外源性肺表面活性物质治疗新生儿呼吸窘迫综合征研究进展  

Research progress of exogenous pulmonary surfactant in the treatment of neonatal respiratory distress syndrome

作　　者：钱文亚 谢晓恬[1] QIAN Wenya, Reviser： XIE Xiaotian(Department of Pediatrics, Tongji Hospital, Medical School, Tongji University, Shanghai 200065, Chin)

机构地区：[1]上海同济大学附属同济医院儿科,上海200065

出　　处：《临床儿科杂志》2018年第6期476-479,共4页Journal of Clinical Pediatrics

摘　　要：外源性肺表面活性物质(PS)替代治疗在新生儿呼吸窘迫综合征(NRDS)中的应用已较多,且疗效确定。但是关于给药剂量、给药时机及给药方式上仍存在争议。文章综述了近3年来国内外有关PS在NRDS中的应用的研究进展,为临床制定诊治策略提供依据。Exogenous pulmonary surfactant（PS） has been widely applied in the treatment of neonatal respiratory distress syndrome（NRDS）, and its curative effect was confirmed. However, there is still controversy about the dosage, timing of administration and the routes of administration. This article reviews the progress of the application of PS in NRDS in recent 3 years, and provides a basis for strategies of clinical diagnosis and treatment.

关 键 词：外源性肺表面活性物质 新生儿呼吸窘迫综合征 替代治疗 

分 类 号：R722.1[医药卫生—儿科]